Abstract
Neurophysiological indicators of Alzheimer’s disease include the presence of aggregated amyloid-beta (Aβ) peptide plaques and low levels of the neurotransmitter, acetylcholine, resulting in cognitive impairment. Acetylcholinesterase has been implicated in not only the aggregation of extracellular Aβ peptides through the enzyme’s peripheral anionic site, but also the hydrolysis of acetylcholine at its catalytic active site. Two components in a methanolic extract of black walnuts (Juglians nigra), gallic and ellagic acids, were found to prevent aggregation of Aβ peptides in the presence of acetylcholinesterase and to disaggregate previously formed oligomers. In addition, both compounds inhibited acetylcholinesterase activity, thus retaining higher acetylcholine concentrations. Analysis of phenolic structures related to gallic acid indicated that 1,3,5-trisubstituted phenolic rings conferred these inhibitory effects on acetylcholinesterase, and thus may provide a structural model on which to design dual inhibitors for both acetylcholinesterase catalytic activity and Aβ aggregation and disaggregation.
Keywords: Acetylcholinesterase, aggregation, amyloid-beta, phenol, dual inhibitors, Alzheimer’s disease.
Current Enzyme Inhibition
Title:Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation
Volume: 9 Issue: 1
Author(s): Caroline M. Peckels, Nathan S. Alexander, Gina N. Wilson, Joel M. Karty and Kathryn M. Matera
Affiliation:
Keywords: Acetylcholinesterase, aggregation, amyloid-beta, phenol, dual inhibitors, Alzheimer’s disease.
Abstract: Neurophysiological indicators of Alzheimer’s disease include the presence of aggregated amyloid-beta (Aβ) peptide plaques and low levels of the neurotransmitter, acetylcholine, resulting in cognitive impairment. Acetylcholinesterase has been implicated in not only the aggregation of extracellular Aβ peptides through the enzyme’s peripheral anionic site, but also the hydrolysis of acetylcholine at its catalytic active site. Two components in a methanolic extract of black walnuts (Juglians nigra), gallic and ellagic acids, were found to prevent aggregation of Aβ peptides in the presence of acetylcholinesterase and to disaggregate previously formed oligomers. In addition, both compounds inhibited acetylcholinesterase activity, thus retaining higher acetylcholine concentrations. Analysis of phenolic structures related to gallic acid indicated that 1,3,5-trisubstituted phenolic rings conferred these inhibitory effects on acetylcholinesterase, and thus may provide a structural model on which to design dual inhibitors for both acetylcholinesterase catalytic activity and Aβ aggregation and disaggregation.
Export Options
About this article
Cite this article as:
M. Peckels Caroline, S. Alexander Nathan, N. Wilson Gina, M. Karty Joel and M. Matera Kathryn, Trisubstituted Phenolic Compounds as Inhibitors of Acetylcholinesterase and Amyloid Beta Aggregate Formation, Current Enzyme Inhibition 2013; 9 (1) . https://dx.doi.org/10.2174/1573408011309010009
DOI https://dx.doi.org/10.2174/1573408011309010009 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Current Diabetes Reviews Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology The Effects of Combined Omega-3 Fatty Acids and Valproic Acid Supplementation on Symptoms of Borderline Personality Disorder: A Pilot Study
Current Psychopharmacology Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets The Cellular Protective Effects of Rosmarinic Acid: From Bench to Bedside
Current Neurovascular Research Synthesis and Biological Evaluation of Hexahydropyrrolo[2,3-b]Indole Derivatives as Fungicides against Phytopathogenic Fungi
Combinatorial Chemistry & High Throughput Screening Meet Our Editorial Board Member
Current Alzheimer Research Ligand and Structure-Based Drug Design as Strategies for the Screening of New BACE1 Inhibitor Candidates
Current Physical Chemistry Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Preface: Central Nicotinic Receptors and their Ligands: Setting the Scene
Current Topics in Medicinal Chemistry A Role of the Parasympathetic Nervous System in Cognitive Training
Current Alzheimer Research Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design The Effects of Exposure to Recent Autobiographical Events on Declarative Memory in Amnestic Mild Cognitive Impairment: A Preliminary Pilot Study
Current Alzheimer Research NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimers Disease
Current Pharmaceutical Design Drug Delivery Systems for Prevention and Treatment of Osteoporotic Fracture
Current Drug Targets Beyond Estrogen: Targeting Gonadotropin Hormones in the Treatment of Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery